Literature DB >> 7860202

The value of prognostic factors in prostatic cancer.

J Schubert1, S Kowalik.   

Abstract

Several prognostic parameters of prostatic carcinoma needed to help guide treatment in individual patients are discussed. Tumour volume, nodal and bone metastases, grading, prostate-specific antigen and DNA ploidy have been correlated with prognosis. Recent studies have analysed tumour volume in detail. However, currently there is no single prognostic factor which can predict tumour aggressiveness on an individual patient basis to rationalize decisions. Multivariate analyses are therefore in progress to determine independent prognostic variables.

Entities:  

Mesh：

Year:  1994        PMID： 7860202     DOI： 10.1007/bf02767656

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  42 in total

1.  Problems of grading carcinoma of prostate.

Authors:  F K Mostofi
Journal:  Semin Oncol       Date:  1976-06       Impact factor: 4.929

2.  The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer.

Authors:  T G Armitage; E H Cooper; D W Newling; M R Robinson; I Appleyard
Journal:  Br J Urol       Date:  1988-12

Review 3.  Steroid receptor and biochemical profiles in prostatic cancer: correlation with response to hormonal treatment.

Authors:  E R Barrack; C B Brendler; P C Walsh
Journal:  Prog Clin Biol Res       Date:  1987

4.  [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].

Authors:  T A Stamey
Journal:  Urologe A       Date:  1990-03       Impact factor: 0.639

5.  Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer.

Authors:  Y Arai; T Yoshiki; H Yamabe; O Yoshida
Journal:  Urol Int       Date:  1990       Impact factor: 2.089

6.  Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer.

Authors:  O van Aubel; J Bolt-de Vries; M A Blankenstein; F H Schröder
Journal:  Prostate       Date:  1988       Impact factor: 4.104

7.  Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients.

Authors:  L S Gorelic; D L Lamm; I Ramzy; H M Radwin; S A Shain
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

8.  Grading of prostatic cancer: III. Multivariate analysis of prognostic parameters.

Authors:  F H Schroeder; W C Hop; J H Blom; F K Mostofi
Journal:  Prostate       Date:  1985       Impact factor: 4.104

9.  Combined histologic grading of prostatic carcinoma.

Authors:  A Böcking; J Kiehn; M Heinzel-Wach
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

10.  Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma.

Authors:  D D Fentie; W H Lakey; W A McBlain
Journal:  J Urol       Date:  1986-01       Impact factor: 7.450
View more
  1 in total

1.  The prognostic importance of prostate specific antigen in the monitorisation of patients undergoing maximum androgen blockade for metastatic prostate cancer.

Authors:  Ahmet Kiper; Orhan Yiğitbasi; Abdurrahim Imamoglu; Can Tuygun; Celaleddin Turan
Journal:  Int Urol Nephrol       Date:  2006-12-13       Impact factor: 2.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.